Mandia, Daniele
Plaze, Marion
Le Ber, Isabelle
Ewenczyk, Claire
Morin, Alexandre
Carle, Guilhem
Consoli, Angèle
Degardin, Adrian
Amad, Ali
Moreau, Caroline
Anheim, Mathieu
Tranchant, Christine
Mélé, Nicolas
Roue-Jagot, Carole
Lagarde, Julien
Sarazin, Marie
Hamelin, Lorraine
Ellul, Pierre
Pagan, Cécile
Pettazzoni, Magali
Bekri, Soumeya
Belliard, Serge
Goizet, Cyril
Wallon, David
Lamari, Foudil
Nadjar, Yann http://orcid.org/0000-0003-1466-6957
Funding for this research was provided by:
Actelion Pharmaceuticals
Article History
Received: 11 April 2020
Revised: 20 June 2020
Accepted: 22 June 2020
First Online: 26 June 2020
Compliance with ethical standards
:
: Dr Marion Plaze, Mathieu Anheim, Cécile Pagan, Cyril Goizet, and Yann Nadjar received travel grants and/or honoraria from Actelion Pharmaceuticals, which manufactures the drug Miglustat, used in NP-C; Mathieu Anheim also received honoraria and/or grants from Johnson and Johnson which is now part of Actelion Pharmaceuticals. Dr Daniele Mandia, Caroline Moreau, Isabelle Le Ber, Claire Ewenczyk, Alexandre Morin, Guilhem Carle, Angèle Consoli, Adrian Degardin, Ali Amad, Mathieu Anheim, Christine Tranchant, Nicolas Mélé, Carole Roue Jagot, Julien Lagarde, Marie Sarazin, Lorraine Hamelin, Pierre Ellul, Soumeya Bekri, Serge Belliard, David Wallon, and Foudil Lamari report no conflicts of interests relevant to this manuscript.
: This study has been approved by the appropriate ethics committee.
: All patients gave their informed consent prior to their inclusion in the study.